Next Article in Journal
Dipropargyl 2,2'-isophthaloylbis(hydrazinecarboxylate)
Previous Article in Journal
8-[2-(1H-indol-3-yl)vinyl]-10,10-dimethyl-10H-pyrido[1,2-a] indolium Perchlorate
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Short Note


Ravinesh Mishra
Anees A. Siddiqui
Mohammad Shaharyar
Asif Husain
Mohd Rashid
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110062, India
Author to whom correspondence should be addressed.
Molbank 2010, 2010(4), M700;
Submission received: 9 October 2010 / Accepted: 21 October 2010 / Published: 25 October 2010


6-Phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydro-pyridazin-3(2H)-one 3 has been synthesized by a sequence of reactions starting from 6-oxo-3-phenyl-5,6-dihydropyridazine-1(4H)-carbohydrazide 1. The structure of the title compound 3 was established on the basis of IR, 1H-NMR, 13C-NMR and mass spectral data.

Graphical Abstract

The chemistry of 4,5-dihydro-3(2H)-pyridazinone has been an interesting field of study since decades. The synthesis of novel pyridazinone derivatives and investigation of their chemical and biological behavior have gained more importance in recent decades for biological, medicinal, and agricultural reasons. Living organisms have difficulties in the construction of N-N bonds that limits the natural abundance of compounds having such bonds. Pyridazinone derivatives, a class of compounds containing the N-N bond, exhibit a wide range of pharmacological activities such as antidepressant [1], antihypertensive [2,3], antithrombotic [4], anticonvulsant [5], cardiotonic [6], antibacterial [7], diuretic [8], anti-HIV [9] and anticancer [10]. Some pyridazinone derivatives like indolidan [11], bemoradan [12], primobendan [13], levosimendan [14] are already approved in the clinical market. The current work describes the synthesis of 6-phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one (3).
The purity of the compounds was checked by single-spot TLC, and the compounds were characterized on the basis of spectral data (IR, 1H-NMR, MS) and elemental analysis. Spectral data of the synthesized compound 3 was in full agreement with its proposed structure. The IR spectra revealed NH, CH, C=S, C=O and C=N absorption bands at 3323, 2930, 2368, 1685 and 1607 cm-1, respectively. In the 1H-NMR spectra, the signals of the respective protons of the title compound were verified on the basis of their chemical shifts, multiplicities, and coupling constants. The two triplets at δ 2.54 and 2.99 confirmed the presence of methylene protons at C-4 and C-5 position of the pyridazinone ring, respectively. The multiplet at δ 7.13–7.93 is due to the aromatic protons. The singlet at δ 10.78 is due to the hydrogen of the CSNH group. The 13C-NMR spectrum showed peaks at δ 177 and δ 186 for a carbonyl carbon and a thioxo carbon. The mass spectrum shows the presence of a peak at m/z 350 (M+ + 1) in accordance with the molecular formula. The elemental analysis results were within ±0.4% of the theoretical values. The starting material, 6-oxo-3-phenyl-5,6-dihydropyridazine-1(4H)-carbo-hydrazide 1 was synthesized based on a literature method [15].

Synthesis of 6-phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one 3

An ethanolic solution of 6-oxo-3-phenyl-5,6-dihydropyridazine-1(4H)-carbohydrazide 1 (0.01 mol) and phenyl isothiocyanate (0.01 mol) was refluxed for 4 h. The contents were concentrated and poured into crushed ice, filtered and dried to give the crude thiosemicarbazide intermediate as 2-[(6-oxo-3-phenyl-5,6-dihydropyridazin-1(4H)-yl)carbonyl]-N-phenylhydrazinecarbothioamide 2. The crude thio-semi-carbazide intermediate 2 (0.005 mol) was refluxed in 2M sodium hydroxide solution (20 mL) for 5 h, cooled, poured into water with continuous stirring and filtered to give the final compound 3 as follows: the filtrate on acidification with glacial acetic acid yielded a solid which was recrystallized from ethanol. The purity of compound 3 was checked by TLC, using toluene/ethyl acetate/formic acid (5:4:1) as mobile phase and iodine (I2) as visualizing agent.
Yield: 40%; m.p. 180–182 °C; Rf 0.42; white amorphous solid.
IR (KBr) υmax (cm−1): 3323 (NH), 2930 (CH), 2368 (C=S), 1685 (C=O), 1607 (C=N), 1030.
1H-NMR (300 MHz, CDCl3): δ 2.54 (t, J = 8.7 Hz, 2H, CH2), 2.99 (t, J = 8.7 Hz, 2H, CH2), 7.13–7.93 (m, 10H, Ar-H), 10.78 (s, 1H, CSNH).
13C-NMR (75 MHz, CDCl3): δ 27.1, 33.2, 124.5, 125.3, 128.6, 128.8, 129, 130.8, 131.2, 139.4, 154, 155, 155.6, 177 (C=O), 186 (C=S).
ESI-MS (m/z): 349/350 (M+/M++1).
Anal Calcd. for C18H15N5OS: C: 61.87; H: 4.33; N: 20.04. Found: C: 61.82; H: 4.22; N: 19.96.

Supplementary materials

Supplementary File 1Supplementary File 2Supplementary File 3


One of the authors (Ravinesh Mishra) expresses sincere thanks to the University Grant Commission (UGC), New Delhi, India, for the award of Research Fellowship in Science for Meritorious Students (RFSMS). The authors are also thankful to Jamia Hamdard, New Delhi, India for providing facility for the research work.


  1. Coelho, A.; Sotelo, E.; Ravina, E. Pyridazine derivatives. Part 33: Sonogashira approaches in the synthesis of 5-substituted-6-phenyl-3(2H)-pyridazinones. Tetrahedron 2003, 59, 2477–2484. [Google Scholar] [CrossRef]
  2. Demirayak, S.; Karaburun, A.C.; Beis, R. Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. Eur. J. Med. Chem. 2004, 39, 1089–1095. [Google Scholar] [CrossRef] [PubMed]
  3. Siddiqui, A.A.; Mishra, R.; Shaharyar, M. Synthesis, characterization and antihypertensive activity of pyridazinone derivatives. Eur. J. Med. Chem. 2010, 45, 2283–2290. [Google Scholar] [CrossRef] [PubMed]
  4. Monge, A.; Parrado, P.; Font, M.; Alvarez, E.F. Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinotriazino[4,5-a]indole, and related compounds. J. Med. Chem. 1987, 30, 1029–1035. [Google Scholar] [CrossRef] [PubMed]
  5. Rubat, C.; Coudert, P.; Refouvelet, B.; Tronche, P.; Bastide, P. Anticonvulsant activity of 3-oxo-5-substituted benzylidene-6-methyl-(4H)-2-pyridazinylacetamides and 2-pyridazinylacetyl-hydrazides. Chem. Pharm. Bull. 1990, 38, 3009–3013. [Google Scholar] [CrossRef] [PubMed]
  6. Sircar, I.; Weishaar, R.E.; Kobylarz, D.; Moos, W.H.; Bristol, J.A. Cardiotonic agents. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity. J. Med. Chem. 1987, 30, 1955–1962. [Google Scholar] [PubMed]
  7. Longo, J.G.; Verde, I.; Castro, M.E. Pyridazine derivatives XIV. Study of the vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta: Comparison with hydralazine. J. Pharm. Sci. 1993, 82, 286–290. [Google Scholar]
  8. Akahane, A.; Katayama, H.; Mitsunaga, T. Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic acid (FK 838): A novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity. J. Med. Chem. 1999, 42, 779–783. [Google Scholar] [CrossRef] [PubMed]
  9. Livermone, D.G.H.; Bethell, R.C.; Cammack, N. Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines. J. Med. Chem. 1993, 36, 3784–3794. [Google Scholar] [CrossRef]
  10. Malinka, W.; Redzicka, A.; Lozach, O. New derivatives of pyrrolo[3,4-d]pyridazinone and their anticancer effects. Il Farmaco 2004, 59, 457–462. [Google Scholar] [CrossRef] [PubMed]
  11. Abouzid, K.; Hakeem, M.A.; Khalil, O.; Maklad, Y. Pyridazinone derivatives: Design, synthesis, and in vitro vasorelaxant activity. Bioorg. Med. Chem. 2008, 16, 382–389. [Google Scholar] [CrossRef] [PubMed]
  12. Combs, D.W.; Rampulla, M.S.; Bell, S.C.; Klaubert, D.H.; Tobia, A.J.; Falotico, R.; Haertlein, B.; Weiss, C.L.; Moore, J.B. 6-Benzoxazinylpyridazin-3-ones: Potent, long-acting positive inotrope and peripheral vasodilator agents. J. Med. Chem. 1990, 22, 380–386. [Google Scholar] [CrossRef]
  13. Robertson, D.W.; Jones, N.D.; Krushinski, J.H.; Pollock, G.D.; Swartzendruber, J.K.; Hayes, J.S. Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one, a potent inhibitor of cyclic AMP phospho-diesterase. J. Med. Chem. 1987, 30, 623–627. [Google Scholar] [CrossRef] [PubMed]
  14. Archan, S.; Toller, W. Levosimendan: current status and future prospects. Curr. Opin. Anesthesiol. 2008, 21, 78–84. [Google Scholar] [CrossRef] [PubMed]
  15. Mishra, R.; Siddiqui, A.A.; Kumar, R.; Kumar, S. 6-Oxo-3-phenyl-5,6-dihydropyridazine-1(4H)-carbohydrazide. Molbank 2010, 2010, M652. [Google Scholar] [CrossRef]
Figure 1. Synthetic route to the title compound 3.
Figure 1. Synthetic route to the title compound 3.
Molbank 2010 m700 g001

Share and Cite

MDPI and ACS Style

Mishra, R.; Siddiqui, A.A.; Shaharyar, M.; Husain, A.; Rashid, M. 6-Phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one. Molbank 2010, 2010, M700.

AMA Style

Mishra R, Siddiqui AA, Shaharyar M, Husain A, Rashid M. 6-Phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one. Molbank. 2010; 2010(4):M700.

Chicago/Turabian Style

Mishra, Ravinesh, Anees A. Siddiqui, Mohammad Shaharyar, Asif Husain, and Mohd Rashid. 2010. "6-Phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one" Molbank 2010, no. 4: M700.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop